the last part of their release related to rvx
"The agreement achieved with the FDA on the pivotal
clinical trial design is expected to enhance the
current and ongoing partnership discussions for
RVX-208"
wondering how much it will "enhance"
the "ongoing partnership discussions for RVX-208"?
p.s hepa's been working it's way back to their 52 week
high the last month - trading so far this evening
continues to bring it a wee bit closer ...
the link https://www.bloomberg.com/press-releases/2020-06-29/hepalink-announces-exciting-regulatory-developments